First-pass extracted concept

in situ and in vivo CAR engineering platforms

Candidate: concept label1 source documents3 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

in situ CAR engineering platforms, in vivo CAR engineering platforms

Evidence Snippets

Emerging in situ and in vivo CAR engineering platforms aim to overcome these barriers by programming patient immune cells directly within the body.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1capabilitysupports2026Source 1DOI PubMed

In situ and in vivo CAR engineering platforms aim to overcome autologous manufacturing barriers by programming patient immune cells directly within the body.

Quoted textsource-backed

Emerging in situ and in vivo CAR engineering platforms aim to overcome these barriers by programming patient immune cells directly within the body.

Claim 2challengesupports2026Source 1DOI PubMed

Key challenges for these emerging CAR delivery and allogeneic approaches include cell-specific targeting, control of transgene persistence, immunogenicity, and regulatory considerations.

Quoted textsource-backed

Despite this promise, challenges remain, including cell-specific targeting, control of transgene persistence, immunogenicity, and regulatory considerations.

Claim 3limitationsupports2026Source 1DOI PubMed

Autologous ex vivo CAR-T cell therapies are limited by individualized manufacturing complexity and cost.

Quoted textsource-backed

The success of ex vivo chimeric antigen receptor (CAR)-T cell therapies has transformed the treatment of hematologic malignancies but remains limited by individualized manufacturing complexity and cost.